Dhanvantri Jeev.

Why is Dhanvantri Jeevan Rekha Ltd falling/rising?

As of 09-Jul, Dhanvantri Jeevan Rekha Ltd's stock price is rising to Rs 27.45 after a trend reversal, despite an initial loss. The stock shows strong relative performance, trading above key moving averages, with increased investor participation indicating growing confidence.

As of 09-Jul, Dhanvantri Jeevan Rekha Ltd's stock price is rising, currently at Rs 27.45, reflecting an increase of Rs 1.2 or 4.57%. This upward movement follows a trend reversal after two consecutive days of decline. Although the stock opened with a loss of 4.69% today, it managed to reach an intraday high of Rs 27.45, indicating a recovery during the trading session.<BR><BR>The stock has outperformed the sector by 3.4%, which suggests strong relative performance compared to its peers. Additionally, Dhanvantri Jeevan Rekha Ltd is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a positive trend in the stock's performance over various time frames. <BR><BR>Investor participation has also increased, with a delivery volume of 3.47k on 08 Jul, which is up by 4.3% compared to the 5-day average delivery volume. This suggests growing interest and confidence among investors in the stock. Overall, these factors contribute to the stock's rise despite the initial opening loss.

Which are the latest news on Dhanvantri Jeev.?

Should I buy, sell or hold Dhanvantri Jeevan Rekha Ltd?

How big is Dhanvantri Jeev.?

As of 10th June, Dhanvantri Jeevan Rekha Ltd has a market capitalization of 8.00 Cr, with Net Sales of 25.86 Cr and a Net Profit of 0.39 Cr reported in the latest four quarters. Shareholder's Funds are 10.13 Cr and Total Assets are 14.75 Cr as of March 2025.

As of 10th June, Dhanvantri Jeevan Rekha Ltd has a market capitalization of 8.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 25.86 Cr and a Net Profit of 0.39 Cr.<BR><BR>For the latest annual period ending in March 2025, Shareholder's Funds amounted to 10.13 Cr, while Total Assets were reported at 14.75 Cr.

Who are in the management team of Dhanvantri Jeev.?

The management team of Dhanvantri Jeev includes V S Phull and Shalini Sharma as Managing Directors, along with several other directors and officers, such as Premjit S Kashyap (Chairman), Ashokkumar Singh Chaudhary, and Ritika Bhandari (Company Secretary). This team is responsible for overseeing the company's operations and governance.

The management team of Dhanvantri Jeev includes the following individuals:<BR><BR>1. **V S Phull** - Managing Director<BR>2. **Shalini Sharma** - Managing Director<BR>3. **Meenaakashi Elhence** - Non-Executive & Non-Independent Director<BR>4. **Premjit S Kashyap** - Chairman (Non-Executive)<BR>5. **Ashokkumar Singh Chaudhary** - Non-Executive & Independent Director<BR>6. **Ajay Rajpal** - Non-Executive & Independent Director<BR>7. **Ritika Bhandari** - Company Secretary & Compliance Officer<BR>8. **Anil Elhence** - Director<BR>9. **Rowena Sharma** - Director<BR>10. **Tulsi Prasad** - Director<BR>11. **Mohd Haaris** - Director<BR>12. **Amitabh Krishna Bhatia** - Additional Director<BR><BR>This team oversees the operations and governance of the company.

Who are the peers of the Dhanvantri Jeev.?

The peers of Dhanvantri Jeev. include Transgene Biotek, Adeshwar Meditex, Family Care, Vanta Bioscience, Looks Health, Clinitech Lab, Dr Lalchand. Lab, Ashram Online, and Gian Lifecare. Dhanvantri Jeev. has an average management risk and a 1-year return of -7.25%, better than Gian Lifecare's -62.42% but worse than Looks Health's 96.39%.

Peers: The peers of Dhanvantri Jeev. are Transgene Biotek, Adeshwar Meditex, Family Care, Vanta Bioscience, Looks Health, Clinitech Lab, Dr Lalchand. Lab, Ashram Online, and Gian Lifecare.<BR><BR>Quality Snapshot: Excellent management risk is observed at Family Care, while Average management risk is found at Adeshwar Meditex and Dhanvantri Jeev., and Below Average management risk is noted at Transgene Biotek, Vanta Bioscience, Clinitech Lab, Dr Lalchand. Lab, and Gian Lifecare, along with the rest. Good growth is seen at Family Care, while Below Average growth is noted at Adeshwar Meditex, Transgene Biotek, Vanta Bioscience, Clinitech Lab, Dr Lalchand. Lab, Dhanvantri Jeev., and Gian Lifecare, and the rest do not qualify. Good capital structure is observed at Family Care, Clinitech Lab, Dr Lalchand. Lab, and Gian Lifecare, while Average capital structure is found at Adeshwar Meditex, and the rest do not qualify.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Looks Health at 96.39%, while Gian Lifecare has the lowest at -62.42%. Dhanvantri Jeev.'s 1-year return of -7.25% is better than Gian Lifecare's but worse than Looks Health's. Additionally, the six-month return is negative for Transgene Biotek, Adeshwar Meditex, Family Care, Vanta Bioscience, Clinitech Lab, Dr Lalchand. Lab, Ashram Online, and Gian Lifecare.

What does Dhanvantri Jeev. do?

Dhanvantri Jeevan Rekha Ltd is a micro-cap multi-speciality hospital offering diagnostic and therapeutic services, with recent net sales of 7 Cr and a market cap of 8 Cr. The company has been operational since 1993 and reported a net profit of 0 Cr for the quarter ending March 2026.

Overview:<BR>Dhanvantri Jeevan Rekha Ltd is a multi-speciality hospital providing reliable diagnostic and therapeutical services in the healthcare services industry, categorized as a micro-cap company.<BR><BR>History:<BR>Incorporated on June 11, 1993, Dhanvantri Jeevan Rekha Ltd has been operational for approximately 30 years. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 7 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 8 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 21.00 <BR>Industry P/E: 81 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.34 <BR>Return on Equity: 3.71% <BR>Price to Book: 0.78 <BR><BR>Contact Details:<BR>Address: 1 Saket, Meerut, Uttar Pradesh: 250003 <BR>Phone: 91-0121-2648151/2648152 <BR>Email: dhanvantrihospital@gmail.com <BR>Website: http://www.djrl.org.in

When is the next results date for Dhanvantri Jeevan Rekha Ltd?

The next results date for Dhanvantri Jeevan Rekha Ltd is 28 May 2026.

The next results date for Dhanvantri Jeevan Rekha Ltd is scheduled for 28 May 2026.

Are Dhanvantri Jeevan Rekha Ltd latest results good or bad?

Dhanvantri Jeevan Rekha Ltd's latest Q3 FY26 results show strong revenue growth and a significant increase in net profit, but ongoing challenges with low return on equity and a high P/E ratio suggest caution for investors. Overall, the results present a mixed outlook.

Dhanvantri Jeevan Rekha Ltd's latest results for Q3 FY26 show a mix of positive developments and ongoing challenges. On the positive side, the company reported a net profit of ₹0.17 crore, which represents a remarkable 221.43% increase quarter-on-quarter and a 13.33% increase year-on-year. Additionally, net sales reached ₹7.27 crores, marking a strong 27.54% year-on-year growth and the highest quarterly figure in two years.<BR><BR>The operating margin improved to 3.99%, the highest in eight quarters, indicating a recovery in operational performance. However, despite these positive indicators, the company faces significant structural challenges. The average return on equity (ROE) remains low at 2.25%, which is below industry standards, and the return on capital employed (ROCE) is negative at -4.36%, suggesting issues with capital efficiency.<BR><BR>Moreover, the company's high P/E ratio of 104x raises concerns about its valuation, especially when compared to the healthcare services industry average of 59x. This valuation appears stretched given the company's underlying profitability and growth trajectory.<BR><BR>In summary, while the recent quarterly results indicate a recovery and growth in revenue, the company's persistent capital efficiency issues and high valuation present a mixed picture. Investors should weigh these factors carefully when assessing the company's performance.

Is Dhanvantri Jeev. overvalued or undervalued?

As of November 17, 2025, Dhanvantri Jeev is considered risky and overvalued with a PE ratio of 103.48, low ROE of 1.00%, negative ROCE of -2.81%, and a PEG ratio of 0.00, despite a 23.17% stock return over the past year, suggesting caution for investors.

As of 17 November 2025, Dhanvantri Jeev's valuation grade has moved from very attractive to risky, indicating a significant shift in its perceived investment quality. The company is currently overvalued, with a price-to-earnings (PE) ratio of 103.48, which is substantially higher than peers like Apollo Hospitals at 64.41 and Max Healthcare at 77.22. Additionally, the EV to EBITDA ratio stands at 9.21, which, while not excessively high, still reflects a premium compared to the industry average.<BR><BR>In terms of performance metrics, Dhanvantri Jeev has a return on equity (ROE) of 1.00% and a return on capital employed (ROCE) of -2.81%, both of which are concerning and suggest inefficiencies in generating returns relative to its equity and capital. The company's PEG ratio is 0.00, indicating no growth expectations factored into its valuation, further supporting the conclusion that it is overvalued. Despite recent stock performance showing a 23.17% return over the past year compared to the Sensex's 9.50%, the underlying financial ratios and peer comparisons suggest that investors should approach Dhanvantri Jeev with caution.

How has been the historical performance of Dhanvantri Jeev.?

Dhanvantri Jeev has shown positive growth in net sales, increasing from 16.77 Cr in Mar'22 to 22.65 Cr in Mar'25, while profitability has fluctuated, with profit after tax improving from a loss of -1.42 Cr in Mar'21 to a profit of 0.51 Cr in Mar'25. Despite growth in sales, the company’s financial metrics indicate the need for ongoing monitoring and strategic management.

Answer:<BR>The historical performance of Dhanvantri Jeev shows a fluctuating trend in net sales and profitability over the years.<BR><BR>Breakdown:<BR>Dhanvantri Jeev's net sales have increased from 16.77 Cr in Mar'22 to 22.65 Cr in Mar'25, indicating a positive growth trajectory. The total operating income followed a similar pattern, rising from 16.77 Cr in Mar'22 to 22.65 Cr in Mar'25. However, the operating profit (PBDIT) has shown volatility, peaking at 1.71 Cr in Mar'22 before declining to 1.12 Cr in Mar'25. Profit before tax also fluctuated, with a notable loss of -1.63 Cr in Mar'21, but rebounded to 0.56 Cr in Mar'25. Profit after tax improved from a loss of -1.42 Cr in Mar'21 to a profit of 0.51 Cr in Mar'25. The company's total assets decreased slightly from 15.02 Cr in Mar'24 to 14.75 Cr in Mar'25, while total liabilities also saw a decline from 15.02 Cr to 14.75 Cr in the same period. Cash flow from operating activities has been positive, with a net cash inflow of 2.00 Cr in Mar'24, reflecting improved liquidity. Overall, while Dhanvantri Jeev has experienced growth in sales and a recovery in profitability, its financial metrics indicate a need for continued monitoring and strategic management.

What is the technical trend for Dhanvantri Jeev.?

As of May 30, 2025, Dhanvantri Jeev's trend has shifted to a moderate bearish stance, supported by bearish momentum in the MACD, moving averages, and KST indicators, along with mildly bearish Bollinger Bands on both weekly and monthly time frames.

As of 30 May 2025, the technical trend for Dhanvantri Jeev has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. Key indicators driving this include the weekly MACD showing bearish momentum, daily moving averages confirming a bearish trend, and the KST on a weekly basis also indicating bearish conditions. The Bollinger Bands are mildly bearish on both weekly and monthly time frames, reinforcing the overall bearish outlook. The Dow Theory suggests a mildly bearish trend on the weekly chart, while the monthly chart shows no clear trend.

Who are the top shareholders of the Dhanvantri Jeev.?

The top shareholders of Dhanvantri Jeev include promoter Anil Elhence with 6.76% and public shareholder Rowena Sharma with 9.43%. Individual investors collectively hold 42.34%, with no mutual funds or foreign institutional investors involved, and no pledged promoter holdings.

The top shareholders of Dhanvantri Jeev include Anil Elhence, who is the promoter with the highest holding at 6.76%. The highest public shareholder is Rowena Sharma, holding 9.43%. Additionally, individual investors collectively hold 42.34% of the company's shares. There are no mutual funds or foreign institutional investors currently holding shares in the company, and there are no pledged promoter holdings.

Has Dhanvantri Jeev. declared dividend?

Dhanvantri Jeevan Rekha Ltd has declared a 4% dividend, amounting to 0.4100 per share, with an ex-date of September 15, 2011. However, the dividend yield is 0%, and total returns over various periods show significant price growth despite the lack of dividend income.

Dhanvantri Jeevan Rekha Ltd has declared a 4% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 4%<BR>- Amount per share: 0.4100<BR>- Ex-date: Sep-15-2011<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -27.48%, the dividend return was 0%, resulting in a total return of -27.48%.<BR><BR>In the 1-year period, the price return was 5.94%, the dividend return was 0%, resulting in a total return of 5.94%.<BR><BR>In the 2-year period, the price return was 39.92%, the dividend return was 0%, resulting in a total return of 39.92%.<BR><BR>In the 3-year period, the price return was 39.92%, the dividend return was 0%, resulting in a total return of 39.92%.<BR><BR>In the 4-year period, the price return was 204.44%, the dividend return was 0%, resulting in a total return of 204.44%.<BR><BR>In the 5-year period, the price return was 212.43%, the dividend return was 0%, resulting in a total return of 212.43%.<BR><BR>Overall, while Dhanvantri Jeevan Rekha Ltd has declared a dividend, the dividend yield remains at 0%. The total returns over various periods show a significant increase in price returns, particularly over the longer term, indicating potential growth despite the lack of dividend yield.